Japan Medical Dynamic Marketing, Inc. (JP:7600)
:7600
Want to see JP:7600 full AI Analyst Report?
Top Page
Japan Medical Dynamic Marketing, Inc.
(7600)
Select Model
Select Model
Rating:49Neutral
Price Target:
¥729.00
▲(49.69% Upside)
Action:Reiterated
Date:05/19/26
The score is primarily held back by weakened fundamentals—sharp margin compression and severely negative free cash flow—alongside a high P/E that amplifies downside risk if performance does not recover. Technicals are modestly supportive due to price strength above moving averages, but mixed momentum indicators keep the uplift limited.
Positive Factors
Balance Sheet Strength
A large equity base and moderate leverage (debt/equity ~0.23 in 2026) provide financial flexibility and downside resilience. This supports funding of working capital, targeted capex or M&A without immediate refinancing stress, preserving strategic optionality over months.
Negative Factors
Revenue Deceleration
A shift from multi-year growth to a YoY revenue decline undermines scale advantages and raises the risk that fixed costs will pressure margins. Continued top-line weakness limits reinvestment capability and makes sustainable margin recovery more difficult over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A large equity base and moderate leverage (debt/equity ~0.23 in 2026) provide financial flexibility and downside resilience. This supports funding of working capital, targeted capex or M&A without immediate refinancing stress, preserving strategic optionality over months.
Read all positive factors
Japan Medical Dynamic Marketing, Inc. (7600) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥18.67B
Dividend Yield3.12%
Average Volume (3M)89.74K
Price to Earnings (P/E)53.8
Beta (1Y)0.54
Revenue Growth-4.77%
EPS GrowthN/A
CountryJP
Employees511
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-25.42
Shares Outstanding26,475,880
10 Day Avg. Volume96,020
30 Day Avg. Volume89,743
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)0.56
Price to Sales (P/S)0.59
P/FCF Ratio-8.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)18.2
Revenue Forecast (FY)¥25.30B
Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model
Company Description
Japan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan and the United States. The company provides trauma devices, including nails, screws, plates, and other products surgically implanted in the f...
How the Company Makes Money
null...
Japan Medical Dynamic Marketing, Inc. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
63
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.98B | 23.92B | 25.11B | 23.18B | 21.31B | 19.19B |
| Gross Profit | 14.46B | 12.74B | 15.65B | 14.76B | 13.99B | 12.99B |
| EBITDA | 1.03B | 2.19B | 1.40B | 3.27B | 3.35B | 4.21B |
| Net Income | -669.47M | 263.14M | -461.80M | 1.27B | 1.42B | 2.14B |
Balance Sheet | ||||||
| Total Assets | 32.22B | 35.68B | 33.83B | 31.49B | 29.43B | 27.34B |
| Cash, Cash Equivalents and Short-Term Investments | 2.35B | 3.11B | 3.18B | 2.32B | 2.80B | 2.59B |
| Total Debt | 4.31B | 5.87B | 3.29B | 1.49B | 1.87B | 1.85B |
| Total Liabilities | 8.25B | 10.25B | 9.09B | 5.88B | 6.14B | 5.85B |
| Stockholders Equity | 23.96B | 25.40B | 24.68B | 25.51B | 23.16B | 21.39B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.75B | -504.10M | 302.45M | 870.67M | 1.53B |
| Operating Cash Flow | 0.00 | 205.55M | 1.05B | 2.10B | 2.19B | 3.11B |
| Investing Cash Flow | 0.00 | -2.00B | -1.67B | -1.80B | -1.48B | -1.75B |
| Financing Cash Flow | 0.00 | 1.65B | 1.49B | -840.71M | -514.78M | -1.29B |
Japan Medical Dynamic Marketing, Inc. Technical Analysis
Positive
487.00
Price Trends
563.08
Positive
531.33
Positive
514.00
Positive
Market Momentum
29.18
Negative
66.95
Neutral
80.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Positive. The current price of 487 is below the 20-day moving average (MA) of 564.60, below the 50-day MA of 563.08, and below the 200-day MA of 514.00, indicating a bullish trend. The MACD of 29.18 indicates Negative momentum. The RSI at 66.95 is Neutral, neither overbought nor oversold. The STOCH value of 80.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7600.
Japan Medical Dynamic Marketing, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥17.91B | 15.06 | ― | 3.02% | 13.43% | 7.06% | |
61 Neutral | ¥249.58B | 16.30 | ― | 1.92% | 4.29% | 3.92% | |
55 Neutral | ¥96.14B | 27.16 | ― | 2.31% | 3.35% | 74.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥18.67B | 53.77 | ― | 3.12% | -4.77% | ― | |
49 Neutral | ¥54.89B | 362.92 | -0.46% | ― | -12.27% | ― | |
47 Neutral | ¥130.02B | 279.88 | 2.42% | 3.73% | 0.78% | -95.37% |
* Healthcare Sector Average
JP:7600
Japan Medical Dynamic Marketing, Inc.
718.00
199.68
38.52%
JP:7779
CYBERDYNE
274.00
101.00
58.38%
JP:6523
PHC Holdings Corp.
1,044.00
125.25
13.63%
JP:4549
Eiken Chemical Co., Ltd.
3,005.00
1,059.80
54.48%
JP:6678
Techno Medica Co., Ltd.
2,086.00
352.69
20.35%
JP:6849
Nihon Kohden Corporation
1,494.00
-134.71
-8.27%
Japan Medical Dynamic Marketing, Inc. Corporate Events
Japan Medical Dynamic Marketing Denies Report of Launching Take-Private Bid
May 13, 2026
Japan Medical Dynamic Marketing, Inc. has refuted a recent paid English-language media report claiming the company has launched a bidding process to go private, stating that the information did not originate from the company. Management acknowledg...
Japan Medical Dynamic Marketing Sets Out FY2026 Results and RT500 Long-Term Plan
May 12, 2026
Japan Medical Dynamic Marketing has released materials for its financial results briefing for the fiscal year ended March 2026, detailing consolidated net sales, income statements, and sales breakdowns by major product categories and regions, incl...
Japan Medical Dynamic Marketing Swings to Profit but Warns of Sharper Earnings Decline Ahead
May 8, 2026
Japan Medical Dynamic Marketing reported a 4.8% decline in net sales to ¥23.9 billion for the year ended March 31, 2026, with operating profit dropping 63.1% to ¥574 million and ordinary profit down 64.1%, though it swung to a profit att...
Japan Medical Dynamic Marketing Misses Forecasts but Holds Dividend as Deferred Tax Write-Down Weighs on Profit
May 8, 2026
Japan Medical Dynamic Marketing reported that its full-year results for the fiscal year ended March 31, 2026 fell short of its earlier forecasts, with net sales and operating profit declining due to fewer surgical cases in Japan following adverse ...
Japan Medical Dynamic Marketing Reshapes Auditor Lineup to Bolster Governance
Mar 27, 2026
Japan Medical Dynamic Marketing, Inc. announced a change in its audit structure following the resignation of full-time auditor Katsuhiko Seshita, effective March 31, 2026, due to personal reasons. As of April 1, 2026, Yoshiaki Jitto will become a ...
Japan Medical Dynamic Marketing Overhauls Governance and Executive Lineup
Mar 27, 2026
Japan Medical Dynamic Marketing, Inc. will shift its governance structure from a company with a Board of Company Auditors to a company with an Audit and Supervisory Committee, pending shareholder approval at its June 19, 2026 annual meeting. The b...
Japan Medical Dynamic Marketing Plans Governance Shift and Electronic Disclosure Move
Mar 27, 2026
Japan Medical Dynamic Marketing will ask shareholders at its June 19, 2026 annual meeting to approve a shift from a traditional company auditor structure to a Company with an Audit and Supervisory Committee and to move its public notices to an ele...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.